Journal Article (Review Article)

DZNE-2025-01467

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The evolving landscape of Alzheimer's disease therapy: From Aβ to tau.

Courade, J.-P. ; Zetterberg, H. ; Höglinger, G. U.DZNE* ; Dewachter, I.

2025
Cell Press [Cambridge, Mass.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.cell.2025.11.033

Abstract: A marked evolution in Alzheimer's disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.

Keyword(s): Alzheimer Disease: therapy (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Alzheimer Disease: drug therapy (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Humans (MeSH) ; tau Proteins: metabolism (MeSH) ; tau Proteins: antagonists & inhibitors (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Amyloid beta-Peptides: antagonists & inhibitors (MeSH) ; Immunotherapy: methods (MeSH) ; Animals (MeSH) ; Clinical Trials as Topic (MeSH) ; A(I)TN ; ASO ; AT(X)N ; ATN ; Abeta therapy ; Alzheimer's disease ; PET imaging ; amyloid ; anti-sense oligonucleotides ; clinical trial ; immunization ; inflammation ; neurodegeneration ; next-generation therapies ; tau ; tau therapy ; tauopathies ; therapy development ; trial ; tau Proteins ; Amyloid beta-Peptides

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 60 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---